组织蛋白酶K抑制剂Odanacatib的研究进展

被引：3

作者：

崔敏

于灵芝

机构：

[1] 山东大学附属济南市中心医院疼痛科

来源：

中华骨质疏松和骨矿盐疾病杂志 | 2011年 / 4卷 / 04期

关键词：

组织蛋白酶K; Odanacatib; 骨质疏松症; 抑制剂;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

组织蛋白酶K是一种在破骨细胞高表达的溶酶体蛋白酶,在骨胶原的降解过程中发挥关键作用。临床前研究证实,组织蛋白酶K抑制剂可以逆转去卵巢动物的骨量流失,恢复其骨强度。Odanacatib是一种高度选择性的组织蛋白酶K抑制剂,几乎不产生硬斑病样皮肤病变。一项为期3年、对绝经后骨量减少或骨质疏松症的临床研究发现,较之安慰剂组,Odanacatib治疗组的骨密度明显升高,治疗效果与目前广泛应用的双膦酸盐等抗吸收药物相当,除此之外还具有不抑制骨形成的优点。

引用

页码：264 / 268

页数：5

共 10 条

[1]

Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect [J].

Eisman, John A. ;

Bone, Henry G. ;

Hosking, David J. ;

McClung, Michael R. ;

Reid, Ian R. ;

Rizzoli, Rene ;

Resch, Heinrich ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Petrovic, Romana ;

Santora, Arthur C. ;

Ince, B. Avery ;

Lombardi, Antonio .

JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (02) :242-251

[2]

The Cathepsin K Inhibitor AAE581 Induces Morphological Changes in Osteoclasts of Treated Patients [J].

Chappard, Daniel ;

Libouban, Helene ;

Mindeholm, Linda ;

Basle, Michel F. ;

Legrand, Erick ;

Audran, Maurice .

MICROSCOPY RESEARCH AND TECHNIQUE, 2010, 73 (07) :726-732

[3]

New treatment targets in osteoporosis [J].

Roux, Sophie .

JOINT BONE SPINE, 2010, 77 (03) :222-228

[4]

Effects of odanacatib on bone turnover and osteoclast morphology in the lumbar vertebra of ovariectomized adult rhesus monkeys.[J].K.R. Scott;B. Pennypacker;T. Cusick;L.T. Duong*;D.B. Kimmel.Bone.2009,

[5]

Two year results in a randomized; double-blind; placebo-controlled study of odanacatib (MK-822) in postmenopausal women with low bone mineral density.[J].J.A. Eisman;R.R. Recker;M. McClung;H. Bone;C. Roux;N. Verbruggen;C.M. Hustad;C. DaSilva;A. Santora;A. Ince.Bone.2009,

[6]

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study [J].

Vasikaran, S. D. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (08) :1457-1458

[7]

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial [J].

Miller, Paul D. ;

Bolognese, Michael A. ;

Lewiecki, E. Michael ;

McClung, Michael R. ;

Ding, Beiying ;

Austin, Matthew ;

Liu, Yu ;

Martin, Javier San .

BONE, 2008, 43 (02) :222-229

[8]

Drug-induced morphea: Report of a case induced by balicatib and review of the literature [J].

Peroni, Anna ;

Zini, Antonio ;

Braga, Vania ;

Colato, Chiara ;

Adami, Silvano ;

Girolomoni, Giampiero .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (01) :125-129

[9]

Decreased Bone Turnover and Deterioration of Bone Structure in Two Cases of Pycnodysostosis.[J].Nadja Fratzl-Zelman;Angelika Valenta;Paul Roschger;Alexander Nader;Bruce D. Gelb;Peter Fratzl;Klaus Klaushofer.The Journal of Clinical Endocrinology & Metabolism.2004, 4

[10]

Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study [J].

Sornay-Rendu, E ;

Garnero, P ;

Munoz, F ;

Duboeuf, F ;

Delmas, PD .

BONE, 2003, 33 (01) :159-166

← 1 →